companydata.dkAdaptVac ApS: Financial statements 2025
CVR: 38732730
AdaptVac ApS (CVR 38732730) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity amounted to DKK 10,808,696. The solvency ratio was 47%. The company had 7 employees in the financial year.
- Gross Profit
- -3,160,505 kr.
- Profit/Loss
- -7,053,665 kr.
- Equity
- 10,808,696 kr.
- Total Assets
- 22,975,523 kr.
- Employees
- 7
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -3.2 mio. | -7.1 mio. | 10.8 mio. | 7 |
| 2024 | - | 8.4 mio. | 1.7 mio. | 17.9 mio. | 6 |
| 2023 | - | 69.2 mio. | 50.9 mio. | 58.6 mio. | 6 |
| 2022 | - | -1.6 mio. | -4.8 mio. | 7.8 mio. | 6 |
| 2021 | - | 1.3 mio. | -1.8 mio. | 12.6 mio. | 5 |
Find more companies like AdaptVac ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2025
AdaptVac ApS has published its annual report for 2024. Gross profit came to DKK 8,392,621, and the net result was DKK 1,714,349.
About AdaptVac ApS
AdaptVac ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Willem Adriaan De Jongh and Adam Frederik Sander Bertelsen. The company is owned by EXPRES2ION BIOTECHNOLOGIES ApS and NextGen Vaccines Holding ApS. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity amounted to DKK 10,808,696.